title: Controlled Dual Drug Release and In Vitro Cytotoxicity of Electrospun Poly(lactic-co-glycolic acid) Nanofibers Encapsulated with Micelles.
abstract: In order to realize controlled dual release of two hydrophobic drugs with distinct rates in a vehicle, novel poly(lactic-co-glycolic acid) (PLGA) composite nanofibers encapsulated with micelles were successfully fabricated by "emulsion-electrospinning." Brefeldin A (BFA) was firstly embedded in monomethoxy-poly(ethylene glycol)-b-poly(L-lactide) (MePEG-PLLA) micelles. By means of "emulsion-electrospinning," paclitaxel (PTX) and polymeric micelles contained BFA were successfully loaded into the electrospun PLGA composite nanofibers. The in vitro release results demonstrated that the location of the drugs in the electrospun fibers determined their release profiles. BFA had a long-term and sustained release while PTX had a relatively rapid release in the dual drugs delivery system. In vitro cytotoxicity studies revealed that the composite nanofibers with two drugs restrained HepG-2 cells more efficiently. These results strongly suggested that the electrospun composite nanofibers containing polymeric micelles can be used as an effective controlled dual release of hydrophobic drugs and were suitable for postoperative chemotherapy of cancers.
authors: Wanyun
authors: W
authors: Liu
authors: Junchao
authors: J
authors: Wei
authors: Yen
authors: Y
authors: Wei
authors: Yiwang
authors: Y
authors: Chen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000737:chemistry; D020126:Brefeldin A / Q000008:administration & dosage / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000138:chemical synthesis*; D004058:Diffusion; D004595:Electroplating; D056945:Hep G2 Cells; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D008823:Micelles; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry / Q000648:ultrastructure; D057139:Nanofibers / Q000737:chemistry* / Q000648:ultrastructure; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012399:Rotation; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D008823:Micelles; D053769:Nanocapsules; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D020126:Brefeldin A; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017239:Paclitaxel